View in EDS

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Saved in:
Bibliographic Details
Title: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Authors: Epstein-Peterson ZD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center., Aypar U; Department of Pathology, Memorial Sloan Kettering Cancer Center., Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Caron P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center., Drullinsky P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Gerecitano J; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Hamlin PA; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Ho C; Department of Pathology, Memorial Sloan Kettering Cancer Center., Jacob A; Adaptive Biotechnologies, Seattle, WA., Joseph A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Laraque L; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Matasar MJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz AJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz CH; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Mullins C; Adaptive Biotechnologies, Seattle, WA., Owens C; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Salles G; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Straus DJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Younes A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Zelenetz AD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Kumar A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center. kumara@mskcc.org.
Source: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1149-1162. Date of Electronic Publication: 2024 Apr 01.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37646671
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Epstein-Peterson+ZD%22">Epstein-Peterson ZD</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Drill+E%22">Drill E</searchLink>; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Aypar+U%22">Aypar U</searchLink>; Department of Pathology, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL%22">Batlevi CL</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Caron+P%22">Caron P</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Dogan+A%22">Dogan A</searchLink>; Department of Pathology, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Drullinsky+P%22">Drullinsky P</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Gerecitano+J%22">Gerecitano J</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Hamlin+PA%22">Hamlin PA</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Ho+C%22">Ho C</searchLink>; Department of Pathology, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Jacob+A%22">Jacob A</searchLink>; Adaptive Biotechnologies, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Joseph+A%22">Joseph A</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Laraque+L%22">Laraque L</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Matasar+MJ%22">Matasar MJ</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Moskowitz+AJ%22">Moskowitz AJ</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Moskowitz+CH%22">Moskowitz CH</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Mullins+C%22">Mullins C</searchLink>; Adaptive Biotechnologies, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Owens+C%22">Owens C</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Salles+G%22">Salles G</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Schöder+H%22">Schöder H</searchLink>; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Straus+DJ%22">Straus DJ</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Younes+A%22">Younes A</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Zelenetz+AD%22">Zelenetz AD</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center.<br /><searchLink fieldCode="AU" term="%22Kumar+A%22">Kumar A</searchLink>; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center. kumara@mskcc.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220417435%22">Haematologica</searchLink> [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1149-1162. <i>Date of Electronic Publication: </i>2024 Apr 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Ferrata+Storti+Foundation%22">Ferrata Storti Foundation </searchLink><i>Country of Publication: </i>Italy <i>NLM ID: </i>0417435 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1592-8721 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203906078%22">03906078 </searchLink><i>NLM ISO Abbreviation: </i>Haematologica <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37646671
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3324/haematol.2023.282898
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1149
    Titles:
      – TitleFull: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Epstein-Peterson ZD
      – PersonEntity:
          Name:
            NameFull: Drill E
      – PersonEntity:
          Name:
            NameFull: Aypar U
      – PersonEntity:
          Name:
            NameFull: Batlevi CL
      – PersonEntity:
          Name:
            NameFull: Caron P
      – PersonEntity:
          Name:
            NameFull: Dogan A
      – PersonEntity:
          Name:
            NameFull: Drullinsky P
      – PersonEntity:
          Name:
            NameFull: Gerecitano J
      – PersonEntity:
          Name:
            NameFull: Hamlin PA
      – PersonEntity:
          Name:
            NameFull: Ho C
      – PersonEntity:
          Name:
            NameFull: Jacob A
      – PersonEntity:
          Name:
            NameFull: Joseph A
      – PersonEntity:
          Name:
            NameFull: Laraque L
      – PersonEntity:
          Name:
            NameFull: Matasar MJ
      – PersonEntity:
          Name:
            NameFull: Moskowitz AJ
      – PersonEntity:
          Name:
            NameFull: Moskowitz CH
      – PersonEntity:
          Name:
            NameFull: Mullins C
      – PersonEntity:
          Name:
            NameFull: Owens C
      – PersonEntity:
          Name:
            NameFull: Salles G
      – PersonEntity:
          Name:
            NameFull: Schöder H
      – PersonEntity:
          Name:
            NameFull: Straus DJ
      – PersonEntity:
          Name:
            NameFull: Younes A
      – PersonEntity:
          Name:
            NameFull: Zelenetz AD
      – PersonEntity:
          Name:
            NameFull: Kumar A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1592-8721
          Numbering:
            – Type: volume
              Value: 109
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Haematologica
              Type: main
ResultId 1